Q4 2025 Karyopharm Therapeutics Inc Earnings Call Transcript

Feb 12, 2026 / 01:00 PM GMT

Release Date Price: $8.94 (+21.30%)

Transcript 10-K8-K

Key Points

Positve

Karyopharm Therapeutics Inc (KPTI) reported a significant increase in total revenue for the fourth quarter of 2025, up by 11.8% compared to the same period in 2024.
The company has a strong commercial foundation in multiple myeloma, with Expovio net product revenue reaching $32.1 million in Q4 2025 and $114.9 million for the full year.
Karyopharm Therapeutics Inc (KPTI) is on track to share top-line data from its phase 3 century trial for myelofibrosis in March 2026, which could establish a new standard of care.
The company is actively preparing for a potential launch in myelofibrosis, with a commercial strategy targeting a multi-billion dollar market opportunity.
Karyopharm Therapeutics Inc (KPTI) has managed to reduce research and development expenses by 17% in Q4 2025 compared to Q4 2024, reflecting disciplined financial management.

Negative

Karyopharm Therapeutics Inc (KPTI) reported a net loss of $102.2 million for Q4 2025 and $196 million for the full year, driven by non-cash items such as loss on extinguishment of debt.
The company's cash position decreased significantly, ending 2025 with $64.1 million compared to $109.1 million at the end of 2024.
Interest expenses increased to $12.6 million in Q4 2025 and $45.8 million for the full year, reflecting higher outstanding debt and interest rates.
The company faces competition in the myelofibrosis market, with Novartis potentially moving forward with its own plans, which could impact Karyopharm's market positioning.
Karyopharm Therapeutics Inc (KPTI) will no longer receive R&D reimbursement from Metarini, which contributed $15 million to 2025 revenue, potentially impacting future financials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

KPTI.OQ - Karyopharm Therapeutics Inc
Q4 2025 Karyopharm Therapeutics Inc Earnings Call
Feb 12, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. My name is Ludy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Curry Farm Therapeutics 4th quarter and full year 2025 financial results conference call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Brandon Strong, senior Vice President, Investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning. And thank you all for joining us on today

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.